These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26022650)

  • 21. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Cencini E; Fabbri A; Bocchia M
    Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
    [No Abstract]   [Full Text] [Related]  

  • 22. How can outcomes be improved for older patients with Hodgkin lymphoma?
    Evens AM; Hong F
    J Clin Oncol; 2013 Apr; 31(12):1502-5. PubMed ID: 23509323
    [No Abstract]   [Full Text] [Related]  

  • 23. Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin's disease.
    Williamson PJ; de Berker D
    Br J Haematol; 2005 Mar; 128(5):582. PubMed ID: 15725077
    [No Abstract]   [Full Text] [Related]  

  • 24. Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin's disease.
    Kömürcü S; Ozet A; Altundag MK; Arpaci F; Oztürk B; Celasun B; Tezcan Y
    Ann Hematol; 2002 Jan; 81(1):57-8. PubMed ID: 11807639
    [No Abstract]   [Full Text] [Related]  

  • 25. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
    Garciaz S; Harel S; Amorim S; Bouabdallah R; Thieblemont C; Brice P
    Br J Haematol; 2016 Nov; 175(4):735-737. PubMed ID: 26685097
    [No Abstract]   [Full Text] [Related]  

  • 26. Radiation in early-stage Hodgkin lymphoma.
    Meyer RM
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):162-89. PubMed ID: 23598983
    [No Abstract]   [Full Text] [Related]  

  • 27. Hodgkin's lymphoma--the great teacher.
    Connors JM
    N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
    [No Abstract]   [Full Text] [Related]  

  • 28. Central nervous system Hodgkin lymphoma developing during systemic chemotherapy.
    Burrows SH; Mannari D
    Br J Haematol; 2016 Jan; 172(2):156. PubMed ID: 26455346
    [No Abstract]   [Full Text] [Related]  

  • 29. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
    Choi Y; Diefenbach CS
    Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
    Fizesan M; Boin C; Aujoulat O; Newinger G; Ghergus D; Watier H; Lustig H; Ojeda-Uribe M
    J Oncol Pharm Pract; 2016 Feb; 22(1):188-92. PubMed ID: 25586990
    [No Abstract]   [Full Text] [Related]  

  • 31. Bilateral sudden hearing loss following ABVD protocol.
    Tazi I; Nafil H; Mahmal L
    J Cancer Res Ther; 2014; 10(1):212. PubMed ID: 24762521
    [No Abstract]   [Full Text] [Related]  

  • 32. Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always.
    Gavini A; Reagan JL; Winer ES; Castillo JJ
    Am J Hematol; 2014 Aug; 89(8):853-7. PubMed ID: 24382755
    [No Abstract]   [Full Text] [Related]  

  • 33. [The practice of chemotherapy with the DeVita protocol].
    Gassmann W; Schmitz N; Löffler H
    Dtsch Med Wochenschr; 1982 Jul; 107(27):1063-9. PubMed ID: 6177488
    [No Abstract]   [Full Text] [Related]  

  • 34. Greater curability in advanced Hodgkin's disease?
    Portlock CS
    Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
    [No Abstract]   [Full Text] [Related]  

  • 35. Autoimmune hemolytic anemia and classical Hodgkin lymphoma: a case report and literature review.
    Feng Q; Zak D; Daya R
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):270-6. PubMed ID: 22706493
    [No Abstract]   [Full Text] [Related]  

  • 36. Angiokeratoma corporis diffusum in a patient with Hodgkin lymphoma: a new paraneoplastic skin manifestation?
    Han F; Wang P; Li Z; Zheng JH; Wang Q; Xu AE; Wang ZM
    Br J Dermatol; 2013 Jun; 168(6):1351-3. PubMed ID: 23278357
    [No Abstract]   [Full Text] [Related]  

  • 37. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic recommendations for early stage Hodgkin lymphomas.
    Depaus J; Delcourt A; André M
    Br J Haematol; 2019 Jan; 184(1):9-16. PubMed ID: 30485401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinblastine for elderly and frail patients with Hodgkin lymphoma.
    Meynard L; Galtier J; Favre S; Debus L; Lascaux A; Dilhuydy MS; Gros FX; Sauvezie M; Milpied N; Bouabdallah K; Dimicoli S
    Leuk Lymphoma; 2020 Dec; 61(13):3239-3242. PubMed ID: 32716269
    [No Abstract]   [Full Text] [Related]  

  • 40. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM; Colonna P
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.